by Raynovich Rod | Jan 14, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools
New Highs in Life Science Sector Life Science stocks are in big rally after the strange sell-off yesterday. The IBB hit a new high today at $244 up 3.67%. Most Rayno Life Science picks are up with significant movers: ALKS up 2%, ALXN up 4%, AMGN up 1.1%, BIIB up...
by Raynovich Rod | Jan 10, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Biotech Bull Market Enters The Bubblet Phase in Early 2014 (Published in Seeking Alpha on January 9) Buyers Anticipating J.P. Morgan Conference: IBB up 3.79% YTD Last week we started a series of articles that will follow key technical and fundamental trends in the...
by Raynovich Rod | Jan 7, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals
Update 1/8/13 Blow-Off anticipating J.P.Morgan Conference? Breakthrough: IBB hit new highs above $230 today. Green screen with most large cap and mid caps. ALKS, BIIB among movers. XBI is also up 2%. Rayno Life Science stocks are in the bullish groove as investors...
by Raynovich Rod | Jan 6, 2014 | Biopharmaceuticals
Celgene (CELG $162) is not on the Rayno biopharmaceutical focus list but it is a good candidate for hedging with a short position or profit taking. Goldman downgraded the stock today from Neutral to SELL . Also, the Wall Street Journal has an article in the...
by Raynovich Rod | Dec 24, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Rayno Life Science Stock Picks Beat The Market Everybody now knows about the bull market in biotech stocks. Innovative products, favorable clinical news, M&A (see below) and breakthrough genomic technologies and targeted therapies have driven most life science...
by Raynovich Rod | Dec 20, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Santa Claus Making Fast Tracks Nasdaq is up 1% as of midday trading and life science stocks are strong across the board. The IBB is up 2.29%, XBI up 1.8 %.The holiday spirit pervades. Movers among the Rayno Life Science focus stocks are the usual suspects plus many...
by Raynovich Rod | Dec 16, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals
But A Lot of Green Today in Diagnostics and Tools The NASDAQ (4030)and the S&P (1787) are up about 0.7% but biotech stocks are lagging with the IBB ($216) up only 0.33%. Momentum in biopharmaceutical stocks has been easing since a late November move around the...
by Raynovich Rod | Dec 12, 2013 | Biopharmaceuticals
Biotech Bull Market Takes A Breather When the biotech bull market began in Q2 2009 it was value driven because of low technology values and Price/Sales for the widely covered stocks. Product sales were about to explode for many companies and in 2012 the sector took...
by Raynovich Rod | Dec 9, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Weak Tape Today 12/10–Gilead (GILD) Down 4.4% on 15.5M Shares IBB ($218.81) down 1.33% on good volume. GILD fall could be reaction to Abbvie (ABBV $53.55) up 4.5% on Phase 3 Hepatitis C data. Virologic response of ABT-450r is 96% in Genotype 1 patients. Other...
by Raynovich Rod | Dec 4, 2013 | Biopharmaceuticals
Life Science Stocks At Ease After 5% Gain in November Stocks Come Back In Late Day Trading 12/4 After 3 down days with the S&P, biotechnology stocks are holding near sector highs with the IBB at $221. Other widely traded ETFS (PBE,XBI) have also held near their...
